Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Inflammation
Published in: Journal of Inflammation 1/2011

Open Access 01-12-2011 | Review

Innate immunity and monocyte-macrophage activation in atherosclerosis

Authors: Joseph Shalhoub, Mika A Falck-Hansen, Alun H Davies, Claudia Monaco

Published in: Journal of Inflammation | Issue 1/2011

Login to get access

Abstract

Innate inflammation is a hallmark of both experimental and human atherosclerosis. The predominant innate immune cell in the atherosclerotic plaque is the monocyte-macrophage. The behaviour of this cell type within the plaque is heterogeneous and depends on the recruitment of diverse monocyte subsets. Furthermore, the plaque microenvironment offers polarisation and activation signals which impact on phenotype. Microenvironmental signals are sensed through pattern recognition receptors, including toll-like and NOD-like receptors thus dictating macrophage behaviour and outcome in atherosclerosis. Recently cholesterol crystals and modified lipoproteins have been recognised as able to directly engage these pattern recognition receptors. The convergent role of such pathways in terms of macrophage activation is discussed in this review.
Appendix
Available only for authorised users
Literature
1.
Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ: Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006, 367 (9524): 1747-57. 10.1016/S0140-6736(06)68770-9.PubMed
2.
Global Burden of Disease Study Operations Manual. 2009, Harvard University, University of Washington, Johns Hopkins University, University of Queensland, World Health Organization
3.
Mayerl C, Lukasser M, Sedivy R, Niederegger H: Atherosclerosis research from past to present--on the track of two pathologists with opposing views, Carl von Rokitansky and Rudolf Virchow. Virchows Archiv. 2006
4.
Methe H, Weis M: Atherogenesis and inflammation--was Virchow right?. Nephrology Dialysis Transplantation. 2007
5.
Ross R: Atherosclerosis--an inflammatory disease. N Engl J Med. 1999, 340 (2): 115-26. 10.1056/NEJM199901143400207.PubMed
6.
Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008, 359 (21): 2195-207. 10.1056/NEJMoa0807646.PubMed
7.
Full L, Ruisanchez C, Monaco C: The inextricable link between atherosclerosis and prototypical inflammatory diseases rheumatoid arthritis and systemic lupus erythematosus. Arthritis Res Ther. 2009, 11 (2): 217-10.1186/ar2631.PubMedPubMedCentral
8.
Haque S, Mirjafari H, Bruce IN: Atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Curr Opin Lipidol. 2008, 19 (4): 338-43. 10.1097/MOL.0b013e328304b65f.PubMed
9.
Glass CK, Witztum JL: Atherosclerosis. the road ahead. Cell. 2001, 104 (4): 503-16. 10.1016/S0092-8674(01)00238-0.PubMed
10.
Caro CG: Discovery of the role of wall shear in atherosclerosis. Arterioscler Thromb Vasc Biol. 2009, 29 (2): 158-61. 10.1161/ATVBAHA.108.166736.PubMed
11.
Cheng C, Tempel D, van Haperen R, van der Baan A, Grosveld F, Daemen MJ, Krams R, de Crom R: Atherosclerotic lesion size and vulnerability are determined by patterns of fluid shear stress. Circulation. 2006, 113 (23): 2744-53. 10.1161/CIRCULATIONAHA.105.590018.PubMed
12.
Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J: Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J. 1993, 69 (5): 377-81. 10.1136/hrt.69.5.377.PubMedPubMedCentral
13.
van der Wal AC, Becker AE, van der Loos CM, Das PK: Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 1994, 89 (1): 36-44.PubMed
14.
Virmani R, Burke AP, Kolodgie FD, Farb A: Pathology of the thin-cap fibroatheroma: a type of vulnerable plaque. J Interv Cardiol. 2003, 16 (3): 267-72. 10.1034/j.1600-0854.2003.8042.x.PubMed
15.
Gleissner CA, Shaked I, Little KM, Ley K: CXC chemokine ligand 4 induces a unique transcriptome in monocyte-derived macrophages. J Immunol. 2010, 184 (9): 4810-8. 10.4049/jimmunol.0901368.PubMedPubMedCentral
16.
Tedgui A, Mallat Z: Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev. 2006, 86 (2): 515-81. 10.1152/physrev.00024.2005.PubMed
17.
Mauriello A, Sangiorgi GM, Virmani R, Trimarchi S, Holmes DR, Kolodgie FD, Piepgras DG, Piperno G, Liotti D, Narula J, Righini P, Ippoliti A, Spagnoli LG: A pathobiologic link between risk factors profile and morphological markers of carotid instability. Atherosclerosis. 2010, 208 (2): 572-80. 10.1016/j.atherosclerosis.2009.07.048.PubMed
18.
Grabner R, Lotzer K, Dopping S, Hildner M, Radke D, Beer M, Spanbroek R, Lippert B, Reardon CA, Getz GS, Fu YX, Hehlgans T, Mebius RE, van der Wall M, Kruspe D, Englert C, Lovas A, Hu D, Randolph GJ, Weih F, Habenicht AJ: Lymphotoxin beta receptor signaling promotes tertiary lymphoid organogenesis in the aorta adventitia of aged ApoE-/- mice. J Exp Med. 2009, 206 (1): 233-48. 10.1084/jem.20080752.PubMedPubMedCentral
19.
Dunmore BJ, McCarthy MJ, Naylor AR, Brindle NP: Carotid plaque instability and ischemic symptoms are linked to immaturity of microvessels within plaques. J Vasc Surg. 2007, 45 (1): 155-9. 10.1016/j.jvs.2006.08.072.PubMed
20.
Narula J, Strauss HW: The popcorn plaques. Nat Med. 2007, 13 (5): 532-4. 10.1038/nm0507-532.PubMed
21.
Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, Abela GS, Franchi L, Nunez G, Schnurr M, Espevik T, Lien E, Fitzgerald KA, Rock KL, Moore KJ, Wright SD, Hornung V, Latz E: NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010, 464 (7293): 1357-61. 10.1038/nature08938.PubMedPubMedCentral
22.
Miller YI, Viriyakosol S, Binder CJ, Feramisco JR, Kirkland TN, Witztum JL: Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells. J Biol Chem. 2003, 278 (3): 1561-8. 10.1074/jbc.M209634200.PubMed
23.
Miller YI, Viriyakosol S, Worrall DS, Boullier A, Butler S, Witztum JL: Toll-like receptor 4-dependent and -independent cytokine secretion induced by minimally oxidized low-density lipoprotein in macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology. 2005, 25 (6): 1213-9. 10.1161/01.ATV.0000159891.73193.31.PubMed
24.
Stewart CR, Stuart LM, Wilkinson K, van Gils JM, Deng J, Halle A, Rayner KJ, Boyer L, Zhong R, Frazier WA, Lacy-Hulbert A, Khoury JE, Golenbock DT, Moore KJ: CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol. 2010, 11 (2): 155-61. 10.1038/ni.1836.PubMedPubMedCentral
25.
Cole JE, Georgiou E, Monaco C: The Expression and Functions of Toll-Like Receptors in Atherosclerosis. Mediators of Inflammation. 2010
26.
Van Ginderachter JA, Movahedi K, Hassanzadeh Ghassabeh G, Meerschaut S, Beschin A, Raes G, De Baetselier P: Classical and alternative activation of mononuclear phagocytes: picking the best of both worlds for tumor promotion. Immunobiology. 2006, 211 (6-8): 487-501. 10.1016/j.imbio.2006.06.002.PubMed
27.
Waldo SW, Li Y, Buono C, Zhao B, Billings EM, Chang J, Kruth HS: Heterogeneity of human macrophages in culture and in atherosclerotic plaques. Am J Pathol. 2008, 172 (4): 1112-26. 10.2353/ajpath.2008.070513.PubMedPubMedCentral
28.
Martinez FO, Gordon S, Locati M, Mantovani A: Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol. 2006, 177 (10): 7303-11.PubMed
29.
Gordon S: Alternative activation of macrophages. Nat Rev Immunol. 2003, 3 (1): 23-35. 10.1038/nri978.PubMed
30.
Gordon S: The macrophage: past, present and future. Eur J Immunol. 2007, 37 (Suppl 1): S9-17.PubMed
31.
Mosser DM, Edwards JP: Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008, 8 (12): 958-69. 10.1038/nri2448.PubMedPubMedCentral
32.
Mantovani A, Garlanda C, Locati M: Macrophage diversity and polarization in atherosclerosis: a question of balance. Arterioscler Thromb Vasc Biol. 2009, 29 (10): 1419-23. 10.1161/ATVBAHA.108.180497.PubMed
33.
Hansson GK: Atherosclerosis An immune disease: The Anitschkov Lecture 2007. Atherosclerosis. 2008, 1-9.
34.
Mallat Z, Taleb S, Ait-Oufella H, Tedgui A: The role of adaptive T cell immunity in atherosclerosis. J Lipid Res. 2009, 50 (Suppl): S364-9.PubMedPubMedCentral
35.
Khallou-Laschet J, Varthaman A, Fornasa G, Compain C, Gaston AT, Clement M, Dussiot M, Levillain O, Graff-Dubois S, Nicoletti A, Caligiuri G: Macrophage plasticity in experimental atherosclerosis. PLoS One. 2010, 5 (1): e8852-10.1371/journal.pone.0008852.PubMedPubMedCentral
36.
Kadl A, Meher AK, Sharma PR, Lee MY, Doran AC, Johnstone SR, Elliott MR, Gruber F, Han J, Chen W, Kensler T, Ravichandran KS, Isakson BE, Wamhoff BR, Leitinger N: Identification of a novel macrophage phenotype that develops in response to atherogenic phospholipids via Nrf2. Circ Res. 2010, 107 (6): 737-46. 10.1161/CIRCRESAHA.109.215715.PubMedPubMedCentral
37.
Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M: The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004, 25 (12): 677-86. 10.1016/j.it.2004.09.015.PubMed
38.
Miller AM, Xu D, Asquith DL, Denby L, Li Y, Sattar N, Baker AH, McInnes IB, Liew FY: IL-33 reduces the development of atherosclerosis. J Exp Med. 2008, 205 (2): 339-46. 10.1084/jem.20071868.PubMedPubMedCentral
39.
Miller AM, Asquith DL, Hueber AJ, Anderson LA, Holmes WM, McKenzie AN, Xu D, Sattar N, McInnes IB, Liew FY: Interleukin-33 induces protective effects in adipose tissue inflammation during obesity in mice. Circ Res. 2010, 107 (5): 650-8. 10.1161/CIRCRESAHA.110.218867.PubMedPubMedCentral
40.
Bouhlel MA, Derudas B, Rigamonti E, Dievart R, Brozek J, Haulon S, Zawadzki C, Jude B, Torpier G, Marx N, Staels B, Chinetti-Gbaguidi G: PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab. 2007, 6 (2): 137-43. 10.1016/j.cmet.2007.06.010.PubMed
41.
Chinetti-Gbaguidi G, Baron M, Bouhlel MA, Vanhoutte J, Copin C, Sebti Y, Derudas B, Mayi T, Bories G, Tailleux A, Haulon S, Zawadzki C, Jude B, Staels B: Human Atherosclerotic Plaque Alternative Macrophages Display Low Cholesterol Handling but High Phagocytosis Because of Distinct Activities of the PPAR{gamma} and LXRα Pathways. Circ Res. 2011
42.
Boyle JJ, Harrington HA, Piper E, Elderfield K, Stark J, Landis RC, Haskard DO: Coronary intraplaque hemorrhage evokes a novel atheroprotective macrophage phenotype. Am J Pathol. 2009, 174 (3): 1097-108. 10.2353/ajpath.2009.080431.PubMedPubMedCentral
43.
Chase AJ, Bond M, Crook MF, Newby AC: Role of nuclear factor-kappa B activation in metalloproteinase-1, -3, and -9 secretion by human macrophages in vitro and rabbit foam cells produced in vivo. Arterioscler Thromb Vasc Biol. 2002, 22 (5): 765-71. 10.1161/01.ATV.0000015078.09208.92.PubMed
44.
Johnson JL, Sala-Newby GB, Ismail Y, Aguilera CM, Newby AC: Low tissue inhibitor of metalloproteinases 3 and high matrix metalloproteinase 14 levels defines a subpopulation of highly invasive foam-cell macrophages. Arterioscler Thromb Vasc Biol. 2008, 28 (9): 1647-53. 10.1161/ATVBAHA.108.170548.PubMedPubMedCentral
45.
Thomas AC, Sala-Newby GB, Ismail Y, Johnson JL, Pasterkamp G, Newby AC: Genomics of foam cells and nonfoamy macrophages from rabbits identifies arginase-I as a differential regulator of nitric oxide production. Arterioscler Thromb Vasc Biol. 2007, 27 (3): 571-7. 10.1161/01.ATV.0000256470.23842.94.PubMed
46.
Gordon S, Martinez FO: Alternative activation of macrophages: mechanism and functions. Immunity. 2010, 32 (5): 593-604. 10.1016/j.immuni.2010.05.007.PubMed
47.
Geissmann F, Jung S, Littman DR: Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity. 2003, 19 (1): 71-82. 10.1016/S1074-7613(03)00174-2.PubMed
48.
Fleming TJ, O'HUigin C, Malek TR: Characterization of two novel Ly-6 genes. Protein sequence and potential structural similarity to alpha-bungarotoxin and other neurotoxins. J Immunol. 1993, 150 (12): 5379-90.PubMed
49.
Strauss-Ayali D, Conrad SM, Mosser DM: Monocyte subpopulations and their differentiation patterns during infection. J Leukoc Biol. 2007, 82 (2): 244-52. 10.1189/jlb.0307191.PubMed
50.
Gautier EL, Jakubzick C, Randolph GJ: Regulation of the migration and survival of monocyte subsets by chemokine receptors and its relevance to atherosclerosis. Arterioscler Thromb Vasc Biol. 2009, 29 (10): 1412-8. 10.1161/ATVBAHA.108.180505.PubMedPubMedCentral
51.
Steinman RM, Idoyaga J: Features of the dendritic cell lineage. Immunol Rev. 2010, 234 (1): 5-17. 10.1111/j.0105-2896.2009.00888.x.PubMed
52.
Passlick B, Flieger D, Ziegler-Heitbrock HW: Identification and characterization of a novel monocyte subpopulation in human peripheral blood. Blood. 1989, 74 (7): 2527-34.PubMed
53.
Ziegler-Heitbrock HW, Fingerle G, Strobel M, Schraut W, Stelter F, Schutt C, Passlick B, Pforte A: The novel subset of CD14+/CD16+ blood monocytes exhibits features of tissue macrophages. Eur J Immunol. 1993, 23 (9): 2053-8. 10.1002/eji.1830230902.PubMed
54.
Ancuta P, Rao R, Moses A, Mehle A, Shaw S, Luscinskas F, Gabuzda D: Fractalkine preferentially mediates arrest and migration of CD16+ monocytes. J Exp Med. 2003, 197 (12): 1701-7. 10.1084/jem.20022156.PubMedPubMedCentral
55.
Weber C, Belge KU, von Hundelshausen P, Draude G, Steppich B, Mack M, Frankenberger M, Weber KS, Ziegler-Heitbrock HW: Differential chemokine receptor expression and function in human monocyte subpopulations. J Leukoc Biol. 2000, 67 (5): 699-704.PubMed
56.
Tacke F, Alvarez D, Kaplan TJ, Jakubzick C, Spanbroek R, Llodra J, Garin A, Liu J, Mack M, van Rooijen N, Lira SA, Habenicht AJ, Randolph GJ: Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest. 2007, 117 (1): 185-94. 10.1172/JCI28549.PubMedPubMedCentral
57.
Palframan RT, Jung S, Cheng G, Weninger W, Luo Y, Dorf M, Littman DR, Rollins BJ, Zweerink H, Rot A, von Andrian UH: Inflammatory chemokine transport and presentation in HEV: a remote control mechanism for monocyte recruitment to lymph nodes in inflamed tissues. J Exp Med. 2001, 194 (9): 1361-73. 10.1084/jem.194.9.1361.PubMedPubMedCentral
58.
Gordon S, Taylor PR: Monocyte and macrophage heterogeneity. Nat Rev Immunol. 2005, 5 (12): 953-64. 10.1038/nri1733.PubMed
59.
Ingersoll MA, Spanbroek R, Lottaz C, Gautier EL, Frankenberger M, Hoffmann R, Lang R, Haniffa M, Collin M, Tacke F, Habenicht AJ, Ziegler-Heitbrock L, Randolph GJ: Comparison of gene expression profiles between human and mouse monocyte subsets. Blood. 2010, 115 (3): e10-9. 10.1182/blood-2009-07-235028.PubMedPubMedCentral
60.
Swirski F, Libby P, Aikawa E, Alcaide P, Luscinskas F, Weissleder R, Pittet M: Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest. 2007, 117 (1): 195-205. 10.1172/JCI29950.PubMedPubMedCentral
61.
Swirski FK, Weissleder R, Pittet MJ: Heterogeneous in vivo behavior of monocyte subsets in atherosclerosis. Arterioscler Thromb Vasc Biol. 2009, 29 (10): 1424-32. 10.1161/ATVBAHA.108.180521.PubMedPubMedCentral
62.
Auffray C, Sieweke MH, Geissmann F: Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol. 2009, 27: 669-92. 10.1146/annurev.immunol.021908.132557.PubMed
63.
Geissmann F, Gordon S, Hume DA, Mowat AM, Randolph GJ: Unravelling mononuclear phagocyte heterogeneity. Nat Rev Immunol. 2010, 10 (6): 453-60. 10.1038/nri2784.PubMedPubMedCentral
64.
Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K: Development of monocytes, macrophages, and dendritic cells. Science. 2010, 327 (5966): 656-61. 10.1126/science.1178331.PubMedPubMedCentral
65.
Nahrendorf M, Swirski FK, Aikawa E, Stangenberg L, Wurdinger T, Figueiredo JL, Libby P, Weissleder R, Pittet MJ: The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med. 2007, 204 (12): 3037-47. 10.1084/jem.20070885.PubMedPubMedCentral
66.
Saederup N, Chan L, Lira SA, Charo IF: Fractalkine deficiency markedly reduces macrophage accumulation and atherosclerotic lesion formation in CCR2-/- mice: evidence for independent chemokine functions in atherogenesis. Circulation. 2008, 117 (13): 1642-8. 10.1161/CIRCULATIONAHA.107.743872.PubMedPubMedCentral
67.
Combadiere C, Potteaux S, Gao JL, Esposito B, Casanova S, Lee EJ, Debre P, Tedgui A, Murphy PM, Mallat Z: Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation. 2003, 107 (7): 1009-16. 10.1161/01.CIR.0000057548.68243.42.PubMed
68.
Lesnik P, Haskell CA, Charo IF: Decreased atherosclerosis in CX3CR1-/- mice reveals a role for fractalkine in atherogenesis. J Clin Invest. 2003, 111 (3): 333-40.PubMedPubMedCentral
69.
Teupser D, Pavlides S, Tan M, Gutierrez-Ramos JC, Kolbeck R, Breslow JL: Major reduction of atherosclerosis in fractalkine (CX3CL1)-deficient mice is at the brachiocephalic artery, not the aortic root. Proc Natl Acad Sci USA. 2004, 101 (51): 17795-800. 10.1073/pnas.0408096101.PubMedPubMedCentral
70.
Boring L, Gosling J, Cleary M, Charo IF: Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. 1998, 394 (6696): 894-7. 10.1038/29788.PubMed
71.
Dawson TC, Kuziel WA, Osahar TA, Maeda N: Absence of CC chemokine receptor-2 reduces atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis. 1999, 143 (1): 205-11. 10.1016/S0021-9150(98)00318-9.PubMed
72.
Kuziel WA, Dawson TC, Quinones M, Garavito E, Chenaux G, Ahuja SS, RL Reddick, Maeda N: CCR5 deficiency is not protective in the early stages of atherogenesis in apoE knockout mice. Atherosclerosis. 2003, 167 (1): 25-32. 10.1016/S0021-9150(02)00382-9.PubMed
73.
Zernecke A, Liehn EA, Gao JL, Kuziel WA, Murphy PM, Weber C: Deficiency in CCR5 but not CCR1 protects against neointima formation in atherosclerosis-prone mice: involvement of IL-10. Blood. 2006, 107 (11): 4240-3. 10.1182/blood-2005-09-3922.PubMed
74.
Combadiere C, Potteaux S, Rodero M, Simon T, Pezard A, Esposito B, Merval R, Proudfoot A, Tedgui A, Mallat Z: Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice. Circulation. 2008, 117 (13): 1649-57. 10.1161/CIRCULATIONAHA.107.745091.PubMed
75.
Wildgruber M, Lee H, Chudnovskiy A, Yoon TJ, Etzrodt M, Pittet MJ, Nahrendorf M, Croce K, Libby P, Weissleder R, Swirski FK: Monocyte subset dynamics in human atherosclerosis can be profiled with magnetic nano-sensors. PLoS One. 2009, 4 (5): e5663-10.1371/journal.pone.0005663.PubMedPubMedCentral
76.
Schlitt A, Heine GH, Blankenberg S, Espinola-Klein C, Dopheide JF, Bickel C, Lackner KJ, Iz M, Meyer J, Darius H, Rupprecht HJ: CD14+CD16+ monocytes in coronary artery disease and their relationship to serum TNF-alpha levels. Thromb Haemost. 2004, 92 (2): 419-24.PubMed
77.
Schirmer SH, Fledderus JO, van der Laan AM, van der Pouw-Kraan TC, Moerland PD, Volger OL, Baggen JM, Bohm M, Piek JJ, Horrevoets AJ, van Royen N: Suppression of inflammatory signaling in monocytes from patients with coronary artery disease. J Mol Cell Cardiol. 2009, 46 (2): 177-85. 10.1016/j.yjmcc.2008.10.029.PubMed
78.
Merino A, Buendia P, Martin-Malo A, Aljama P, Ramirez R, Carracedo J: Senescent CD14+CD16+ Monocytes Exhibit Proinflammatory and Proatherosclerotic Activity. J Immunol. 2011, 186 (3): 1809-15. 10.4049/jimmunol.1001866.PubMed
79.
Kuwana M, Okazaki Y, Kodama H, Izumi K, Yasuoka H, Ogawa Y, Kawakami Y, Ikeda Y: Human circulating CD14+ monocytes as a source of progenitors that exhibit mesenchymal cell differentiation. J Leukoc Biol. 2003, 74 (5): 833-45. 10.1189/jlb.0403170.PubMed
80.
Kamari Y, Shaish A, Shemesh S, Vax E, Grosskopf I, Dotan S, White M, Voronov E, Dinarello CA, Apte RN, Harats D: Reduced atherosclerosis and inflammatory cytokines in apolipoprotein-E-deficient mice lacking bone marrow-derived interleukin-1alpha. Biochem Biophys Res Commun. 2011, 405 (2): 197-203. 10.1016/j.bbrc.2011.01.008.PubMed
81.
Hamilton JA: Rheumatoid arthritis: opposing actions of haemopoietic growth factors and slow-acting anti-rheumatic drugs. Lancet. 1993, 342 (8870): 536-9. 10.1016/0140-6736(93)91653-4.PubMed
82.
Hamilton JA: Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol. 2008, 8 (7): 533-44. 10.1038/nri2356.PubMed
83.
Hashimoto S, Suzuki T, Dong HY, Yamazaki N, Matsushima K: Serial analysis of gene expression in human monocytes and macrophages. Blood. 1999, 94 (3): 837-44.PubMed
84.
Smith JD, Trogan E, Ginsberg M, Grigaux C, Tian J, Miyata M: Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc Natl Acad Sci USA. 1995, 92 (18): 8264-8. 10.1073/pnas.92.18.8264.PubMedPubMedCentral
85.
Stojakovic M, Krzesz R, Wagner AH, Hecker M: CD154-stimulated GM-CSF release by vascular smooth muscle cells elicits monocyte activation--role in atherogenesis. J Mol Med. 2007, 85 (11): 1229-38. 10.1007/s00109-007-0225-y.PubMed
86.
Haghighat A, Weiss D, Whalin MK, Cowan DP, Taylor WR: Granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor exacerbate atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2007, 115 (15): 2049-54. 10.1161/CIRCULATIONAHA.106.665570.PubMed
87.
Zhu SN, Chen M, Jongstra-Bilen J, Cybulsky MI: GM-CSF regulates intimal cell proliferation in nascent atherosclerotic lesions. J Exp Med. 2009, 206 (10): 2141-9. 10.1084/jem.20090866.PubMedPubMedCentral
88.
McLaren JE, Ramji DP: Interferon gamma: a master regulator of atherosclerosis. Cytokine Growth Factor Rev. 2009, 20 (2): 125-35. 10.1016/j.cytogfr.2008.11.003.PubMed
89.
Gupta S, Pablo AM, Jiang X, Wang N, Tall AR, Schindler C: IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J Clin Invest. 1997, 99 (11): 2752-61. 10.1172/JCI119465.PubMedPubMedCentral
90.
Raisanen-Sokolowski A, Glysing-Jensen T, Koglin J, Russell ME: Reduced transplant arteriosclerosis in murine cardiac allografts placed in interferon-gamma knockout recipients. Am J Pathol. 1998, 152 (2): 359-65.PubMedPubMedCentral
91.
Loke P, Nair MG, Parkinson J, Guiliano D, Blaxter M, Allen JE: IL-4 dependent alternatively-activated macrophages have a distinctive in vivo gene expression phenotype. BMC Immunol. 2002, 3: 7-10.1186/1471-2172-3-7.PubMedPubMedCentral
92.
Tabas I: Macrophage death and defective inflammation resolution in atherosclerosis. Nat Rev Immunol. 2010, 10 (1): 36-46.PubMedPubMedCentral
93.
Kreider T, Anthony RM, Urban JF, Gause WC: Alternatively activated macrophages in helminth infections. Curr Opin Immunol. 2007, 19 (4): 448-53. 10.1016/j.coi.2007.07.002.PubMedPubMedCentral
94.
Cordeiro-da-Silva A, Tavares J, Araujo N, Cerqueira F, Tomas A, Kong Thoo Lin P, Ouaissi A: Immunological alterations induced by polyamine derivatives on murine splenocytes and human mononuclear cells. Int Immunopharmacol. 2004, 4 (4): 547-56. 10.1016/j.intimp.2004.02.009.PubMed
95.
Gerber JS, Mosser DM: Reversing lipopolysaccharide toxicity by ligating the macrophage Fc gamma receptors. J Immunol. 2001, 166 (11): 6861-8.PubMed
96.
Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM: Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest. 1998, 101 (4): 890-8. 10.1172/JCI1112.PubMedPubMedCentral
97.
Sternberg EM: Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens. Nat Rev Immunol. 2006, 6 (4): 318-28. 10.1038/nri1810.PubMedPubMedCentral
98.
Liu Y, Cousin JM, Hughes J, Van Damme J, Seckl JR, Haslett C, Dransfield I, Savill J, Rossi AG: Glucocorticoids promote nonphlogistic phagocytosis of apoptotic leukocytes. J Immunol. 1999, 162 (6): 3639-46.PubMed
99.
Mackaness GB: The Immunological Basis of Acquired Cellular Resistance. J Exp Med. 1964, 120: 105-20. 10.1084/jem.120.1.105.PubMedPubMedCentral
100.
Yan ZQ, Hansson GK: Innate immunity, macrophage activation, and atherosclerosis. Immunol Rev. 2007, 219: 187-203. 10.1111/j.1600-065X.2007.00554.x.PubMed
101.
Medzhitov R: Toll-like receptors and innate immunity. Nat Rev Immunol. 2001, 1 (2): 135-45. 10.1038/35100529.PubMed
102.
Medzhitov R, Preston-Hurlburt P, Janeway CA: A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature. 1997, 388 (6640): 394-7. 10.1038/41131.PubMed
103.
Kim TW, Febbraio M, Robinet P, Dugar B, Greene D, Cerny A, Latz E, Gilmour R, Staschke K, Chisolm G, Fox PL, Dicorleto PE, Smith JD, Li X: The Critical Role of IL-1 Receptor-Associated Kinase 4-Mediated NF-{kappa}B Activation in Modified Low-Density Lipoprotein-Induced Inflammatory Gene Expression and Atherosclerosis. J Immunol. 2011, 186 (5): 2871-80. 10.4049/jimmunol.1002242.PubMedPubMedCentral
104.
Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC: CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science. 1990, 249 (4975): 1431-3. 10.1126/science.1698311.PubMed
105.
Tobias PS, Soldau K, Kline L, Lee JD, Kato K, Martin TP, Ulevitch RJ: Cross-linking of lipopolysaccharide (LPS) to CD14 on THP-1 cells mediated by LPS-binding protein. J Immunol. 1993, 150 (7): 3011-21.PubMed
106.
Hoebe K, Georgel P, Rutschmann S, Du X, Mudd S, Crozat K, Sovath S, Shamel L, Hartung T, Zähringer U, Beutler B: CD36 is a sensor of diacylglycerides. Nature. 2005, 433 (7025): 523-7. 10.1038/nature03253.PubMed
107.
Miller YI, Choi SH, Wiesner P, Fang L, Harkewicz R, Hartvigsen K, Boullier A, Gonen A, Diehl CJ, Que X, Montano E, Shaw PX, Tsimikas S, Binder CJ, Witztum JL: Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circ Res. 2011, 108 (2): 235-48. 10.1161/CIRCRESAHA.110.223875.PubMedPubMedCentral
108.
Li M, Carpio DF, Zheng Y, Bruzzo P, Singh V, Ouaaz F, Medzhitov RM, Beg AA: An essential role of the NF-kappa B/Toll-like receptor pathway in induction of inflammatory and tissue-repair gene expression by necrotic cells. J Immunol. 2001, 166 (12): 7128-35.PubMed
109.
Kawakami A, Osaka M, Aikawa M, Uematsu S, Akira S, Libby P, Shimokado K, Sacks FM, Yoshida M: Toll-like receptor 2 mediates apolipoprotein CIII-induced monocyte activation. Circ Res. 2008, 103 (12): 1402-9. 10.1161/CIRCRESAHA.108.178426.PubMedPubMedCentral
110.
Cheng N, He R, Tian J, Ye P, Ye R: Cutting edge: TLR2 is a functional receptor for acute-phase serum amyloid A. J Immunol. 2008, 181 (1): 22-6.PubMedPubMedCentral
111.
Kim S, Takahashi H, Lin WW, Descargues P, Grivennikov S, Kim Y, Luo JL, Karin M: Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature. 2009, 457 (7225): 102-6. 10.1038/nature07623.PubMedPubMedCentral
112.
Seimon TA, Nadolski MJ, Liao X, Magallon J, Nguyen M, Feric NT, Koschinsky ML, Harkewicz R, Witztum JL, Tsimikas S, Golenbock D, Moore KJ, Tabas I: Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. Cell Metab. 2010, 12 (5): 467-82. 10.1016/j.cmet.2010.09.010.PubMedPubMedCentral
113.
Scheibner K, Lutz M, Boodoo S, Fenton M, Powell J, Horton M: Hyaluronan fragments act as an endogenous danger signal by engaging TLR2. J Immunol. 2006, 177 (2): 1272-81.PubMed
114.
Schaefer L, Babelova A, Kiss E, Hausser HJ, Baliova M, Krzyzankova M, Marsche G, Young MF, Mihalik D, Gotte M, Malle E, Schaefer RM, Grone HJ: The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Invest. 2005, 115 (8): 2223-33. 10.1172/JCI23755.PubMedPubMedCentral
115.
Holvoet P, Davey PC, De Keyzer D, Doukouré M, Deridder E, Bochaton-Piallat M-L, Gabbiani G, Beaufort E, Bishay K, Andrieux N, Benhabilès N, Marguerie G: Oxidized low-density lipoprotein correlates positively with toll-like receptor 2 and interferon regulatory factor-1 and inversely with superoxide dismutase-1 expression: studies in hypercholesterolemic swine and THP-1 cells. Arterioscler Thromb Vasc Biol. 2006, 26 (7): 1558-65. 10.1161/01.ATV.0000226553.01555.02.PubMed
116.
Xu XH, Shah PK, Faure E, Equils O, Thomas L, Fishbein MC, Luthringer D, Xu XP, Rajavashisth TB, Yano J, Kaul S, Arditi M: Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation. 2001, 104 (25): 3103-8. 10.1161/hc5001.100631.PubMed
117.
Asea A, Rehli M, Kabingu E, Boch JA, Bare O, Auron PE, Stevenson MA, Calderwood SK: Novel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4. J Biol Chem. 2002, 277 (17): 15028-34. 10.1074/jbc.M200497200.PubMed
118.
Guillot L, Balloy V, McCormack FX, Golenbock DT, Chignard M, Si-Tahar M: Cutting edge: the immunostimulatory activity of the lung surfactant protein-A involves Toll-like receptor 4. J Immunol. 2002, 168 (12): 5989-92.PubMed
119.
Midwood K, Sacre S, Piccinini AM, Inglis J, Trebaul A, Chan E, Drexler S, Sofat N, Kashiwagi M, Orend G, Brennan F, Foxwell B: Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med. 2009, 15 (7): 774-80. 10.1038/nm.1987.PubMed
120.
Smiley ST, King JA, Hancock WW: Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. J Immunol. 2001, 167 (5): 2887-94.PubMed
121.
Okamura Y, Watari M, Jerud ES, Young DW, Ishizaka ST, Rose J, Chow JC, Strauss JF: The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem. 2001, 276 (13): 10229-33. 10.1074/jbc.M100099200.PubMed
122.
Kodaira Y, Nair SK, Wrenshall LE, Gilboa E, Platt JL: Phenotypic and functional maturation of dendritic cells mediated by heparan sulfate. J Immunol. 2000, 165 (3): 1599-604.PubMed
123.
Biragyn A, Ruffini PA, Leifer CA, Klyushnenkova E, Shakhov A, Chertov O, Shirakawa AK, Farber JM, Segal DM, Oppenheim JJ, Kwak LW: Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science. 2002, 298 (5595): 1025-9. 10.1126/science.1075565.PubMed
124.
Cole JE, Navin TJ, Cross AJ, Goddard ME, Alexopoulou L, Mitra AT, Davies AH, Flavell RA, Feldmann M, Monaco C: From the Cover: Unexpected protective role for Toll-like receptor 3 in the arterial wall. Proc Natl Acad Sci USA. 2011, 108 (6): 2372-7. 10.1073/pnas.1018515108.PubMedPubMedCentral
125.
H. Ni, Capodici J, Lamphier M, Weissman D: mRNA is an endogenous ligand for Toll-like receptor 3. J Biol Chem. 2004, 279 (13): 12542-50.
126.
Boule MW, Broughton C, Mackay F, Akira S, Marshak-Rothstein A, Rifkin IR: Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. J Exp Med. 2004, 199 (12): 1631-40. 10.1084/jem.20031942.PubMedPubMedCentral
127.
Leadbetter E, Rifkin I, Hohlbaum A, Beaudette B, Shlomchik M, Marshak-Rothstein A: Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature. 2002, 416 (6881): 603-7. 10.1038/416603a.PubMed
128.
Stewart CR, Stuart LM, Wilkinson K, van Gils JM, Deng J, Halle A, Rayner KJ, Boyer L, Zhong R, Frazier WA, Lacy-Hulbert A, El Khoury J, Golenbock DT, Moore KJ: CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol. 2010, 11 (2): 155-61. 10.1038/ni.1836.PubMedPubMedCentral
129.
Walton KA, Hsieh X, Gharavi N, Wang S, Wang G, Yeh M, Cole AL, Berliner JA: Receptors involved in the oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine-mediated synthesis of interleukin-8. A role for Toll-like receptor 4 and a glycosylphosphatidylinositol-anchored protein. J Biol Chem. 2003, 278 (32): 29661-6. 10.1074/jbc.M300738200.PubMed
130.
Walton KA, Cole AL, Yeh M, Subbanagounder G, Krutzik SR, Modlin RL, Lucas RM, Nakai J, Smart EJ, Vora DK, Berliner JA: Specific phospholipid oxidation products inhibit ligand activation of toll-like receptors 4 and 2. Arterioscler Thromb Vasc Biol. 2003, 23 (7): 1197-203. 10.1161/01.ATV.0000079340.80744.B8.PubMed
131.
Bae YS, Lee JH, Choi SH, Kim S, Almazan F, Witztum JL, Miller YI: Macrophages generate reactive oxygen species in response to minimally oxidized low-density lipoprotein: toll-like receptor 4- and spleen tyrosine kinase-dependent activation of NADPH oxidase 2. Circ Res. 2009, 104 (2): 210-8. 10.1161/CIRCRESAHA.108.181040. 21p following 218PubMedPubMedCentral
132.
Edfeldt K, Swedenborg J, Hansson G, Yan Z: Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation. 2002, 105 (10): 1158-61.PubMed
133.
Schoneveld A, Hoefer I, Sluijter J, Laman J, de Kleijn D, Pasterkamp G: Atherosclerotic lesion development and Toll like receptor 2 and 4 responsiveness. Atherosclerosis. 2008, 197 (1): 95-104. 10.1016/j.atherosclerosis.2007.08.004.PubMed
134.
Geng H, Lu H, Zhang L, Zhang H, Zhou L, Wang H, Zhong R: Increased expression of Toll like receptor 4 on peripheral-blood mononuclear cells in patients with coronary arteriosclerosis disease. Clin Exp Immunol. 2006, 143 (2): 269-73. 10.1111/j.1365-2249.2005.02982.x.PubMedPubMedCentral
135.
Methe H, Kim J, Kofler S, Weis M, Nabauer M, Koglin J: Expansion of circulating Toll-like receptor 4-positive monocytes in patients with acute coronary syndrome. Circulation. 2005, 111 (20): 2654-61. 10.1161/CIRCULATIONAHA.104.498865.PubMed
136.
Shiraki R, Inoue N, Kobayashi S, Ejiri J, Otsui K, Honjo T, Takahashi M, Hirata K, Yokoyama M, Kawashima S: Toll-like receptor 4 expressions on peripheral blood monocytes were enhanced in coronary artery disease even in patients with low C-reactive protein. Life Sci. 2006, 80 (1): 59-66. 10.1016/j.lfs.2006.08.027.PubMed
137.
Kuwahata S, Fujita S, Orihara K, Hamasaki S, Oba R, Hirai H, Nagata K, Ishida S, Kataoka T, Oketani N, Ichiki H, Iriki Y, Saihara K, Okui H, Ninomiya Y, Tei C: High expression level of Toll-like receptor 2 on monocytes is an important risk factor for arteriosclerotic disease. Atherosclerosis. 2009
138.
Ashida K, Miyazaki K, Takayama E, Tsujimoto H, Ayaori M, Yakushiji T, Iwamoto N, Yonemura A, Isoda K, Mochizuki H, Hiraide H, Kusuhara M, Ohsuzu F: Characterization of the expression of TLR2 (toll-like receptor 2) and TLR4 on circulating monocytes in coronary artery disease. J Atheroscler Thromb. 2005, 12 (1): 53-60.PubMed
139.
Liuzzo G, Angiolillo DJ, Buffon A, Rizzello V, Colizzi C, Ginnetti F, Biasucci LM, Maseri A: Enhanced response of blood monocytes to in vitro lipopolysaccharide-challenge in patients with recurrent unstable angina. Circulation. 2001, 103 (18): 2236-41.PubMed
140.
Versteeg D, Hoefer IE, Schoneveld AH, De Kleijn DPV, Busser E, Strijder C, Emons M, Stella PR, Doevendans PA, Pasterkamp G: Monocyte toll-like receptor 2 and 4 responses and expression following percutaneous coronary intervention: association with lesion stenosis and fractional flow reserve. Heart. 2008, 94 (6): 770-776. 10.1136/hrt.2007.117259.PubMed
141.
Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM, Akira S, Rajavashisth TB, Arditi M: Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci USA. 2004, 101 (29): 10679-84. 10.1073/pnas.0403249101.PubMedPubMedCentral
142.
Bjorkbacka H, Kunjathoor VV, Moore KJ, Koehn S, Ordija CM, Lee MA, Means T, Halmen K, Luster AD, Golenbock DT, Freeman MW: Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med. 2004, 10 (4): 416-21. 10.1038/nm1008.PubMed
143.
Monaco C, Gregan SM, Navin TJ, Foxwell BM, Davies AH, Feldmann M: Toll-like receptor-2 mediates inflammation and matrix degradation in human atherosclerosis. Circulation. 2009, 120 (24): 2462-9. 10.1161/CIRCULATIONAHA.109.851881.PubMed
144.
Ishida BY, Blanche PJ, Nichols AV, Yashar M, Paigen B: Effects of atherogenic diet consumption on lipoproteins in mouse strains C57BL/6 and C3H. J Lipid Res. 1991, 32 (4): 559-68.PubMed
145.
Nishina P, Wang J, Toyofuku W, Kuypers F, Ishida B, Paigen B: Atherosclerosis and plasma and liver lipids in nine inbred strains of mice. Lipids. 1993, 28 (7): 599-605. 10.1007/BF02536053.PubMed
146.
Mullick AE, Tobias PS, Curtiss LK: Modulation of atherosclerosis in mice by Toll-like receptor 2. J Clin Invest. 2005, 115 (11): 3149-56. 10.1172/JCI25482.PubMedPubMedCentral
147.
Madan M, Amar S: Toll-like receptor-2 mediates diet and/or pathogen associated atherosclerosis: proteomic findings. PLoS ONE. 2008, 3 (9): e3204-10.1371/journal.pone.0003204.PubMedPubMedCentral
148.
Liu X, Ukai T, Yumoto H, Davey M, Goswami S, Gibson FC, Genco CA: Toll-like receptor 2 plays a critical role in the progression of atherosclerosis that is independent of dietary lipids. Atherosclerosis. 2008, 196 (1): 146-54. 10.1016/j.atherosclerosis.2007.03.025.PubMedPubMedCentral
149.
Vink A, Schoneveld AH, van der Meer JJ, van Middelaar BJ, Sluijter JP, Smeets MB, Quax PH, Lim SK, Borst C, Pasterkamp G, de Kleijn DP: In vivo evidence for a role of toll-like receptor 4 in the development of intimal lesions. Circulation. 2002, 106 (15): 1985-90. 10.1161/01.CIR.0000032146.75113.EE.PubMed
150.
Schoneveld AH, Oude Nijhuis MM, van Middelaar B, Laman JD, de Kleijn DP, Pasterkamp G: Toll-like receptor 2 stimulation induces intimal hyperplasia and atherosclerotic lesion development. Cardiovasc Res. 2005, 66 (1): 162-9. 10.1016/j.cardiores.2004.12.016.PubMed
151.
Shinohara M, Hirata K, Yamashita T, Takaya T, Sasaki N, Shiraki R, Ueyama T, Emoto N, Inoue N, Yokoyama M, Kawashima S: Local overexpression of toll-like receptors at the vessel wall induces atherosclerotic lesion formation: synergism of TLR2 and TLR4. Arterioscler Thromb Vasc Biol. 2007, 27 (11): 2384-91. 10.1161/ATVBAHA.106.139253.PubMed
152.
Shi W, Wang NJ, Shih DM, Sun VZ, Wang X, Lusis AJ: Determinants of atherosclerosis susceptibility in the C3H and C57BL/6 mouse model: evidence for involvement of endothelial cells but not blood cells or cholesterol metabolism. Circ Res. 2000, 86 (10): 1078-84.PubMed
153.
Funk J, Feingold K, Moser A, Grunfeld C: Lipopolysaccharide stimulation of RAW 264.7 macrophages induces lipid accumulation and foam cell formation. Atherosclerosis. 1993, 98 (1): 67-82. 10.1016/0021-9150(93)90224-I.PubMed
154.
Lee JG, Lim EJ, Park DW, Lee SH, Kim JR, Baek SH: A combination of Lox-1 and Nox1 regulates TLR9-mediated foam cell formation. Cell Signal. 2008, 20 (12): 2266-75. 10.1016/j.cellsig.2008.08.022.PubMed
155.
Oiknine J, Aviram M: Increased susceptibility to activation and increased uptake of low density lipoprotein by cholesterol-loaded macrophages. Arterioscler Thromb. 1992, 12 (6): 745-53.PubMed
156.
S Choi, Harkewicz R, Lee J, Boullier A, Almazan F, Li A, Witztum J, Bae Y, Miller Y: Lipoprotein accumulation in macrophages via toll-like receptor-4-dependent fluid phase uptake. Circ Res. 2009, 104 (12): 1355-63. 10.1161/CIRCRESAHA.108.192880.
157.
Bar-Or A, Nuttall RK, Duddy M, Alter A, Kim HJ, Ifergan I, Pennington CJ, Bourgoin P, Edwards DR, Yong VW: Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis. Brain. 2003, 126 (Pt 12): 2738-49.PubMed
158.
Welgus HG, Campbell EJ, Cury JD, Eisen AZ, Senior RM, Wilhelm SM, Goldberg GI: Neutral metalloproteinases produced by human mononuclear phagocytes. Enzyme profile, regulation, and expression during cellular development. J Clin Invest. 1990, 86 (5): 1496-502. 10.1172/JCI114867.PubMedPubMedCentral
159.
Ardans JA, Economou AP, Martinson JM, Zhou M, Wahl LM: Oxidized low-density and high-density lipoproteins regulate the production of matrix metalloproteinase-1 and -9 by activated monocytes. J Leukoc Biol. 2002, 71 (6): 1012-8.PubMed
160.
Saren P, Welgus HG, Kovanen PT: TNF-alpha and IL-1beta selectively induce expression of 92-kDa gelatinase by human macrophages. J Immunol. 1996, 157 (9): 4159-65.PubMed
161.
Herman MP, Sukhova GK, Libby P, Gerdes N, Tang N, Horton DB, Kilbride M, Breitbart RE, Chun M, Schonbeck U: Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. Circulation. 2001, 104 (16): 1899-904. 10.1161/hc4101.097419.PubMed
162.
Shapiro SD, Campbell EJ, Kobayashi DK, Welgus HG: Immune modulation of metalloproteinase production in human macrophages. Selective pretranslational suppression of interstitial collagenase and stromelysin biosynthesis by interferon-gamma. J Clin Invest. 1990, 86 (4): 1204-10. 10.1172/JCI114826.PubMedPubMedCentral
163.
Fabunmi RP, Sukhova GK, Sugiyama S, Libby P: Expression of tissue inhibitor of metalloproteinases-3 in human atheroma and regulation in lesion-associated cells: a potential protective mechanism in plaque stability. Circ Res. 1998, 83 (3): 270-8.PubMed
164.
Guarda G, Braun M, Staehli F, Tardivel A, Mattmann C, Forster I, Farlik M, Decker T, Du Pasquier RA, Romero P, Tschopp J: Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity. 2011, 34 (2): 213-23. 10.1016/j.immuni.2011.02.006.PubMed
165.
Zhang LN, Velichko S, Vincelette J, Fitch RM, Vergona R, Sullivan ME, Croze E, Wang YX: Interferon-beta attenuates angiotensin II-accelerated atherosclerosis and vascular remodeling in apolipoprotein E deficient mice. Atherosclerosis. 2008, 197 (1): 204-11. 10.1016/j.atherosclerosis.2007.03.019.PubMed
166.
Goossens P, Gijbels MJ, Zernecke A, Eijgelaar W, Vergouwe MN, van der Made I, Vanderlocht J, Beckers L, Buurman WA, Daemen MJ, Kalinke U, Weber C, Lutgens E, de Winther MP: Myeloid type I interferon signaling promotes atherosclerosis by stimulating macrophage recruitment to lesions. Cell Metab. 2010, 12 (2): 142-53. 10.1016/j.cmet.2010.06.008.PubMed
167.
Zimmer S, Steinmetz M, Asdonk T, Motz I, Coch C, Hartmann E, Barchet W, Wassmann S, Hartmann G, Nickenig G: Activation of Endothelial Toll-Like Receptor 3 Impairs Endothelial Function. Circ Res. 2011
168.
Koga N, Suzuki J, Kosuge H, Haraguchi G, Onai Y, Futamatsu H, Maejima Y, Gotoh R, Saiki H, Tsushima F, Azuma M, Isobe M: Blockade of the interaction between PD-1 and PD-L1 accelerates graft arterial disease in cardiac allografts. Arterioscler Thromb Vasc Biol. 2004, 24 (11): 2057-62. 10.1161/01.ATV.0000145015.23656.e4.PubMed
169.
Groschel S, Piggott KD, Vaglio A, Ma-Krupa W, Singh K, Goronzy JJ, Weyand CM: TLR-mediated induction of negative regulatory ligands on dendritic cells. J Mol Med. 2008, 86 (4): 443-55. 10.1007/s00109-008-0310-x.PubMedPubMedCentral
170.
Bsibsi M, Bajramovic JJ, Vogt MH, van Duijvenvoorden E, Baghat A, Persoon-Deen C, Tielen F, Verbeek R, Huitinga I, Ryffel B, Kros A, Gerritsen WH, Amor S, van Noort JM: The microtubule regulator stathmin is an endogenous protein agonist for TLR3. J Immunol. 2010, 184 (12): 6929-37. 10.4049/jimmunol.0902419.PubMed
171.
Martinon F, Mayor A, Tschopp J: The inflammasomes: guardians of the body. Annu Rev Immunol. 2009, 27: 229-65. 10.1146/annurev.immunol.021908.132715.PubMed
172.
Wang S, Miura M, Jung YK, Zhu H, Li E, Yuan J: Murine caspase-11, an ICE-interacting protease, is essential for the activation of ICE. Cell. 1998, 92 (4): 501-9. 10.1016/S0092-8674(00)80943-5.PubMed
173.
Mariathasan S, Monack DM: Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation. Nat Rev Immunol. 2007, 7 (1): 31-40. 10.1038/nri1997.PubMed
174.
Burns K, Martinon F, Tschopp J: New insights into the mechanism of IL-1beta maturation. Curr Opin Immunol. 2003, 15 (1): 26-30. 10.1016/S0952-7915(02)00017-1.PubMed
175.
Yajima N, Takahashi M, Morimoto H, Shiba Y, Takahashi Y, Masumoto J, Ise H, Sagara J, Nakayama J, Taniguchi S, Ikeda U: Critical role of bone marrow apoptosis-associated speck-like protein, an inflammasome adaptor molecule, in neointimal formation after vascular injury in mice. Circulation. 2008, 117 (24): 3079-87. 10.1161/CIRCULATIONAHA.107.746453.PubMed
176.
Kirii H, Niwa T, Yamada Y, Wada H, Saito K, Iwakura Y, Asano M, Moriwaki H, Seishima M: Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol. 2003, 23 (4): 656-60. 10.1161/01.ATV.0000064374.15232.C3.PubMed
177.
Elhage R, Jawien J, Rudling M, Ljunggren HG, Takeda K, Akira S, Bayard F, Hansson GK: Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice. Cardiovasc Res. 2003, 59 (1): 234-40. 10.1016/S0008-6363(03)00343-2.PubMed
178.
Devlin CM, Kuriakose G, Hirsch E, Tabas I: Genetic alterations of IL-1 receptor antagonist in mice affect plasma cholesterol level and foam cell lesion size. Proc Natl Acad Sci USA. 2002, 99 (9): 6280-5. 10.1073/pnas.092324399.PubMedPubMedCentral
179.
Dewberry R, Holden H, Crossman D, Francis S: Interleukin-1 receptor antagonist expression in human endothelial cells and atherosclerosis. Arterioscler Thromb Vasc Biol. 2000, 20 (11): 2394-400.PubMed
180.
Ishii N, Matsumura T, Kinoshita H, Fukuda K, Motoshima H, Senokuchi T, Nakao S, Tsutsumi A, Kim-Mitsuyama S, Kawada T, Takeya M, Miyamura N, Nishikawa T, Araki E: Nifedipine induces peroxisome proliferator-activated receptor-gamma activation in macrophages and suppresses the progression of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2010, 30 (8): 1598-605. 10.1161/ATVBAHA.109.202309.PubMed
181.
Nakaya H, Summers BD, Nicholson AC, Gotto AM, Hajjar DP, Han J: Atherosclerosis in LDLR-knockout mice is inhibited, but not reversed, by the PPARgamma ligand pioglitazone. Am J Pathol. 2009, 174 (6): 2007-14. 10.2353/ajpath.2009.080611.PubMedPubMedCentral
182.
Chinetti G, Fruchart JC, Staels B: Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res. 2000, 49 (10): 497-505. 10.1007/s000110050622.PubMed
183.
Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, Morel CR, Subramanian V, Mukundan L, Red Eagle A, Vats D, Brombacher F, Ferrante AW, Chawla A: Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature. 2007, 447 (7148): 1116-20. 10.1038/nature05894.PubMedPubMedCentral
184.
Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM: PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 1998, 93 (2): 241-52. 10.1016/S0092-8674(00)81575-5.PubMed
185.
Straus DS, Glass CK: Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol. 2007, 28 (12): 551-8. 10.1016/j.it.2007.09.003.PubMed
186.
Heilbronn LK, Campbell LV: Adipose tissue macrophages, low grade inflammation and insulin resistance in human obesity. Curr Pharm Des. 2008, 14 (12): 1225-30. 10.2174/138161208784246153.PubMed
187.
Coste A, Dubourdeau M, Linas MD, Cassaing S, Lepert JC, Balard P, Chalmeton S, Bernad J, Orfila C, Seguela JP, Pipy B: PPARgamma promotes mannose receptor gene expression in murine macrophages and contributes to the induction of this receptor by IL-13. Immunity. 2003, 19 (3): 329-39. 10.1016/S1074-7613(03)00229-2.PubMed
188.
Kim SR, Lee KS, Park HS, Park SJ, Min KH, Jin SM, Lee YC: Involvement of IL-10 in peroxisome proliferator-activated receptor gamma-mediated anti-inflammatory response in asthma. Mol Pharmacol. 2005, 68 (6): 1568-75.PubMed
189.
Hetzel M, Walcher D, Grub M, Bach H, Hombach V, Marx N: Inhibition of MMP-9 expression by PPARgamma activators in human bronchial epithelial cells. Thorax. 2003, 58 (9): 778-83. 10.1136/thorax.58.9.778.PubMedPubMedCentral
190.
Marx N, Imhof A, Froehlich J, Siam L, Ittner J, Wierse G, Schmidt A, Maerz W, Hombach V, Koenig W: Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation. 2003, 107 (15): 1954-7. 10.1161/01.CIR.0000069272.06194.91.PubMed
191.
Glatz T, Stock I, Nguyen-Ngoc M, Gohlke P, Herdegen T, Culman J, Zhao Y: Peroxisome-proliferator-activated receptors gamma and peroxisome-proliferator-activated receptors beta/delta and the regulation of interleukin 1 receptor antagonist expression by pioglitazone in ischaemic brain. J Hypertens. 2010, 28 (7): 1488-97. 10.1097/HJH.0b013e3283396e4e.PubMed
192.
Moulin D, Bianchi A, Boyault S, Sebillaud S, Koufany M, Francois M, Netter P, Jouzeau JY, Terlain B: Rosiglitazone induces interleukin-1 receptor antagonist in interleukin-1beta-stimulated rat synovial fibroblasts via a peroxisome proliferator-activated receptor beta/delta-dependent mechanism. Arthritis Rheum. 2005, 52 (3): 759-69. 10.1002/art.20868.PubMed
193.
Halvorsen B, Heggen E, Ueland T, Smith C, Sandberg WJ, Damas JK, Otterdal K, Tonstad S, Aukrust P: Treatment with the PPARgamma agonist rosiglitazone downregulates interleukin-1 receptor antagonist in individuals with metabolic syndrome. Eur J Endocrinol. 2010, 162 (2): 267-73. 10.1530/EJE-09-0706.PubMed
194.
Fernandez AZ: Peroxisome proliferator-activated receptors in the modulation of the immune/inflammatory response in atherosclerosis. PPAR Res. 2008, 2008: 285842-PubMedPubMedCentral
195.
Ziegler-Heitbrock L: The CD14+ CD16+ blood monocytes: their role in infection and inflammation. J Leukoc Biol. 2007, 81 (3): 584-92.PubMed
196.
Yona S, Jung S: Monocytes: subsets, origins, fates and functions. Curr Opin Hematol. 2010, 17 (1): 53-9. 10.1097/MOH.0b013e3283324f80.PubMed
Metadata
Title
Innate immunity and monocyte-macrophage activation in atherosclerosis
Authors
Joseph Shalhoub
Mika A Falck-Hansen
Alun H Davies
Claudia Monaco
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Journal of Inflammation / Issue 1/2011
Electronic ISSN: 1476-9255
DOI
https://doi.org/10.1186/1476-9255-8-9

Other articles of this Issue 1/2011

Journal of Inflammation 1/2011 Go to the issue

Research

T-bet controls severity of hypersensitivity pneumonitis

Research

Zinc supplementation alters airway inflammation and airway hyperresponsiveness to a common allergen

Research

Genetic polymorphism of ACE and the angiotensin II type1 receptor genes in children with chronic kidney disease

Research

Anti-inflammatory and antiproliferative activities of date palm pollen (Phoenix dactylifera) on experimentally-induced atypical prostatic hyperplasia in rats

Research

Vitreous inflammatory factors and serous retinal detachment in central retinal vein occlusion: a case control series

Research

Endotoxin-activated microglia injure brain derived endothelial cells via NF-κB, JAK-STAT and JNK stress kinase pathways
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits